DrugPatentWatch Database Preview
Drugs in Development Information for SJG-136
Development status for investigational drug SJG-136: Patents, clinical trial progress, indications
SJG-136 is an investigational drug.
There have been 4 clinical trials for SJG-136.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Neoplasm Metastasis, Ovarian Neoplasms, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI) and [disabled in preview].
There are forty-nine US patents protecting this investigational drug and five hundred and forty-five international patents.
Summary for SJG-136
| US Patents | 49 |
| International Patents | 545 |
| US Patent Applications | 83 |
| WIPO Patent Applications | 45 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2010-07-01) |
| Vendors | 15 |
Recent Clinical Trials for SJG-136
| Title | Sponsor | Phase |
|---|---|---|
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | National Cancer Institute (NCI) | Phase 2 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 1 |
| SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for SJG-136
Top disease conditions for SJG-136
Top clinical trial sponsors for SJG-136
US Patents for SJG-136
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SJG-136 | Start Trial | Pyrrolobenzodiazepine-antibody conjugates | Medimmune Limited (Cambridge, GB) | Start Trial |
| SJG-136 | Start Trial | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | Start Trial |
| SJG-136 | Start Trial | Humanized anti-Tn-MUC1 antibodies and their conjugates | ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB) | Start Trial |
| SJG-136 | Start Trial | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (Cambridge, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SJG-136
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SJG-136 | Australia | 2014333762 | 2033-10-11 | Start Trial |
| SJG-136 | Australia | 2014333763 | 2033-10-11 | Start Trial |
| SJG-136 | Canada | 2926876 | 2033-10-11 | Start Trial |
| SJG-136 | China | 105636613 | 2033-10-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
